Cargando…

Nefopam prescribing preferences in French hospitals: results of a survey

INTRODUCTION: nefopam is a non-opioid, centrally-acting analgesic, frequently prescribed in France for acute pain and postoperatively. Only intravenous (IV) formulation is available, however the off-label oral use is frequent in surgical and medical patients. There is no data on the actual in-hospit...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulz, Thomas, Lalande, Laure, Aubrun, Frederic, Dziadzko, Mikhail
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167477/
https://www.ncbi.nlm.nih.gov/pubmed/35721644
http://dx.doi.org/10.11604/pamj.2022.41.213.33365
_version_ 1784720806938411008
author Schulz, Thomas
Lalande, Laure
Aubrun, Frederic
Dziadzko, Mikhail
author_facet Schulz, Thomas
Lalande, Laure
Aubrun, Frederic
Dziadzko, Mikhail
author_sort Schulz, Thomas
collection PubMed
description INTRODUCTION: nefopam is a non-opioid, centrally-acting analgesic, frequently prescribed in France for acute pain and postoperatively. Only intravenous (IV) formulation is available, however the off-label oral use is frequent in surgical and medical patients. There is no data on the actual in-hospital prescription preferences in French physicians regarding nefopam. We wish to identify nefopam prescription habits for acute and chronic pain among hospital physicians. METHODS: an online survey was sent to physicians via professional emails. Frequency of prescription, indication, preferred and prescribed administration route, dose regimen, and personal perception of the nefopam tolerance and efficiency were examined. RESULTS: a total of 527 responses were analysed. Nefopam was mostly prescribed by senior hospital physicians, for acute pain, orally (85%), 20 mg/6h with 120 mg maximal daily dose. For chronic pain, the oral administration was more frequent. More than half of prescribers considered the efficacy of the oral route was similar to intravenous, and better tolerated compared to intravenous administration. Forty-eight percent of responders would change their prescription attitude in case of oral route approval of nefopam. CONCLUSION: oral prescription of intravenous formulation of nefopam is frequent, especially for acute pain, and has the same dose and regimen pattern as for intravenous route. Prescribers consider oral nefopam efficient and safe for patients. Regulatory actions regarding the oral nefopam prescription authorization and duration of such prescription are needed.
format Online
Article
Text
id pubmed-9167477
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-91674772022-06-17 Nefopam prescribing preferences in French hospitals: results of a survey Schulz, Thomas Lalande, Laure Aubrun, Frederic Dziadzko, Mikhail Pan Afr Med J Research INTRODUCTION: nefopam is a non-opioid, centrally-acting analgesic, frequently prescribed in France for acute pain and postoperatively. Only intravenous (IV) formulation is available, however the off-label oral use is frequent in surgical and medical patients. There is no data on the actual in-hospital prescription preferences in French physicians regarding nefopam. We wish to identify nefopam prescription habits for acute and chronic pain among hospital physicians. METHODS: an online survey was sent to physicians via professional emails. Frequency of prescription, indication, preferred and prescribed administration route, dose regimen, and personal perception of the nefopam tolerance and efficiency were examined. RESULTS: a total of 527 responses were analysed. Nefopam was mostly prescribed by senior hospital physicians, for acute pain, orally (85%), 20 mg/6h with 120 mg maximal daily dose. For chronic pain, the oral administration was more frequent. More than half of prescribers considered the efficacy of the oral route was similar to intravenous, and better tolerated compared to intravenous administration. Forty-eight percent of responders would change their prescription attitude in case of oral route approval of nefopam. CONCLUSION: oral prescription of intravenous formulation of nefopam is frequent, especially for acute pain, and has the same dose and regimen pattern as for intravenous route. Prescribers consider oral nefopam efficient and safe for patients. Regulatory actions regarding the oral nefopam prescription authorization and duration of such prescription are needed. The African Field Epidemiology Network 2022-03-15 /pmc/articles/PMC9167477/ /pubmed/35721644 http://dx.doi.org/10.11604/pamj.2022.41.213.33365 Text en Copyright: Thomas Schulz et al. https://creativecommons.org/licenses/by/4.0/The Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Schulz, Thomas
Lalande, Laure
Aubrun, Frederic
Dziadzko, Mikhail
Nefopam prescribing preferences in French hospitals: results of a survey
title Nefopam prescribing preferences in French hospitals: results of a survey
title_full Nefopam prescribing preferences in French hospitals: results of a survey
title_fullStr Nefopam prescribing preferences in French hospitals: results of a survey
title_full_unstemmed Nefopam prescribing preferences in French hospitals: results of a survey
title_short Nefopam prescribing preferences in French hospitals: results of a survey
title_sort nefopam prescribing preferences in french hospitals: results of a survey
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167477/
https://www.ncbi.nlm.nih.gov/pubmed/35721644
http://dx.doi.org/10.11604/pamj.2022.41.213.33365
work_keys_str_mv AT schulzthomas nefopamprescribingpreferencesinfrenchhospitalsresultsofasurvey
AT lalandelaure nefopamprescribingpreferencesinfrenchhospitalsresultsofasurvey
AT aubrunfrederic nefopamprescribingpreferencesinfrenchhospitalsresultsofasurvey
AT dziadzkomikhail nefopamprescribingpreferencesinfrenchhospitalsresultsofasurvey